Postdoctoral fellowship in cancer immunology and tumor suppression

The multidisciplinary Blom Research Group, Faculty of Medicine, Lund University is searching for a passionate and skilled postdoctoral fellow to join our groundbreaking work on cancer immunology.

This fellowship offers an opportunity to join cutting-edge cancer research focused on deciphering the role of the tumor suppressor and complement inhibitor CSMD3. You’ll be part of a vibrant team advancing the understanding of molecular underpinnings of cancer.

Why join us?

Comprehensive Postdoctoral Training: this collaborative project presents an outstanding platform for comprehensive training in an array of advanced methodologies. These encompass cutting-edge techniques such as advanced flow cytometry, confocal microscopy, molecular methodologies, including CRISPR/Cas-9 gene editing, investigations into protein interactions, and specialized assays tailored for cancer cell research. For those interested, there is also an option to learn and work with in vivo cancer models.

Collaborative and Supportive Environment: You will collaborate closely with distinguished scientists and clinical partners, gain hands-on mentorship from the group leader, and attend major conferences to showcase your findings and expand your professional network. This mentorship and collaboration will play a pivotal role in not only shaping and refining the project but also in guiding you towards achieving your career aspirations.

Access to Top-tier Facilities: Our lab is located at the cutting-edge Clinical Research Centre, which is fully equipped to support your research ambitions. Additionally, our close ties with Skåne University Hospital provide unique translational research opportunities.

About the Research Group
Our team specializes in exploring immune pathways, especially within cancer and other pathologies. This project combines breakthrough instrumentation, innovative methodologies, and a stimulating, collegial work culture that encourages creative problem-solving and professional growth.

The group’s homepage:

https://www.protein-chemistry.lu.se

 

Lund University and vicinity

Located in vibrant southern Sweden, Lund University ranks among the world’s top 100 institutions and provides a supportive academic community. Our campus in Malmö is ideally situated for easy access to Copenhagen, with a lively, multicultural atmosphere and rich recreational options. No Swedish language skills? No problem – most Swedes speak English fluently.

 

Your Profile

PhD in cancer research, cell biology, immunology, or a related discipline, completed within the last 3 years from the start of the appointment.

Expertise in cancer research, cell biology, immunology and techniques like protein expression, flow cytometry, microscopy, and advanced statistical analysis.

Demonstrated research excellence with first-author publications in peer-reviewed international journals.

Strong communication skills, fluenct in English and a collaborative spirit.

Apply as soon as possible by e-mailing to prof. Anna Blom (anna.blom@med.lu.se) with your CV, publication list and e-mail address of two references.

 

Starting date is flexible but preferably from February 1st 2025.

 

Selected recent publications from the group relevant to the project

Tuysuz E. C., Mourati E., Rosberg R., Gialeli C., Johansson E., Governa V., Belting M., Pietras A., Blom A.M. (2024) The tumor suppressor role of complement inhibitor CSMD1 and its role in TNF-induced neuroinflammation in gliomas., Journal of Experimental and Clinical Cancer Research, 43, 98.

Gialeli C., Tuysuz E., Staaf J., Guleed S., Paciorek V., Mörgelin M., Papadakos K.S. and Blom A.M. (2021) Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer to chemotherapy., Journal of Experimental and Clinical Cancer Research, 40, 258.

Papadakos K.S., Bartoschek M., Rodriguez C., Gialeli C., Jin S., Lendahl U., Pietras K., and Blom A.M. (2019) Cartilage Oligomeric Matrix Protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling., Matrix Biology, 81, 107-121.

Smolag K.I., Olszowka J., Rosberg R., Johansson E., Marinko E., Leandersson K., O´Connel D.J., Governa V., Can Tuysuz E., Belting M., Pietras A., Martin M., and Blom A.M. (2024) Complement factor H is a novel ICOS ligand modulating Tregs in glioma microenvironment., Cancer Immunology Research, doi: 10.1158/2326-6066.CIR-23-1092.